PRAVACHOL
LOE ApproachingNDAORALTABLET
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRAVACHOL (pravastatin) is an oral small-molecule statin approved in 1991 for lipid management. It works by inhibiting HMG-CoA reductase to reduce cholesterol production. The drug is indicated for hypercholesterolemia and cardiovascular risk reduction.
LOE Approaching
Approaching loss of exclusivity with 30% competitive pressure signals declining market opportunity and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRAVACHOL offers limited career growth due to approaching loss of exclusivity and commodity-level competition in the statin market. Positions on this product focus on defending market share and optimizing payer relationships rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on PRAVACHOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.